C3 and hemolytic-uremic syndrome: Indeed, the beneficial effect of C3aR antagonism on attenuating thrombogenic responses in a rodent model of STEC-HUS indicates that upstream complement intervention at the level of C3 might offer broader therapeutic coverage in IA-HUS.